FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102481471> ?p ?o ?g. }

• W2102481471 endingPage "37" @default.
• W2102481471 startingPage "33" @default.
• W2102481471 abstract "Estudio retrospectivo de una serie de pacientes intervenidos mediante adenomectomía prostática suprapúbica (APS) y resección transuretral prostática (RTU-P) bajo el supuesto diagnóstico de HBP sintomática no respondedora al tratamiento médico conservador. Análisis de la prevalencia, incidencia, datos clínico-patológicos, tratamiento, progresión tumoral y evolución de los pacientes con cáncer de próstata incidental (CPI) detectado. Se revisaron 1.593 pacientes intervenidos durante 6 años consecutivos (1996-2001). APS 35%, RTUP 65%. Revisión de todas las anatomías patológicas de los especimenes quirúrgicos y de las evoluciones de los pacientes con CPI. 78 CPI; Prevalencia 4,89%; Incidencia 13 casos/año. Edad media 73,6 años. Tacto rectal normal en todos, PSA medio 6 ng/ml (0,5-30). Grupo APS: 25 CPI (32%); prevalencia 4,55%; incidencia 4 casos/año; PSA medio 7,7 ng/ml (2,8-30); volumen enucleado medio 65 gs. Grupo RTU-P: 53 CPI (68%); prevalencia 5,07%; incidencia 9 casos/año; PSA medio 5,2 ng/ml (0,5-29); volumen resecado medio 20 gs. 22% biopsiados previamente por PSA elevado medio de 14 ng/ml (4,8-30). Mediana de Gleason 5 (media 4,8), rango 3-8. pT1a 66%, pT1b 33%. Tratamiento: 57% seguimiento vigilado sin tratamiento; 18% tratamiento hormonal; 3% finasteride; 9% Prostatectomía Radical; 9% Radioterapia. Pérdidas 4%. Seguimiento medio 47,19 meses (12-96). Progresión tumoral 13,3% (10 pacientes). Mortalidad CPI específica 2,6% (2 pacientes). No observamos diferencias significativas entre la prevalencia de CPI en los dos grupos (APS y RTU-P). Los tumores detectados fueron mayoritariamente bien diferenciados y en estadio pT1a. En más de la mitad de los casos se decidió una actitud expectante sin tratamiento (57%). 13,3% de progresión tumoral tras 47,19 meses de seguimiento medio y mortalidad CPI específica del 2,6%. Retrospective study of a series of patients with prostate surgery (suprapubic prostate adenomectomy –APS-, and prostate transurethral resection -RTU-P- ) for presumed BPH symptomatic non-respondent to the conservative medical treatment. Analysis of prevalence, incidence, clinical-pathological, treatment, tumor progression and evolution of the patients with incidental prostate cancer (CPI) detected. 1593 patients with prostate surgery (APS and RTU-P) during 6 years (1996-2001) were revised. APS 35%, RTU-P 65%. Revision of all pathological anatomy of surgical specimens and the evolutions of the patients with CPI. 78 CPI; Prevalence 4,89%; Incidence 13 cases/year. Mean age 73.6 years. Digital rectal examination was normal in 100%, mean PSA 6 ng/ml (0.5-30). Group APS: 25 CPI (32%); prevalence 4.55%; incidence 4 cases/year; mean PSA 7.7 ng/ml (2.8-30); mean weight resection 65 gs. Group RTU-P: 53 CPI (68%); prevalence 5,07%; incidence 9 cases/year; mean PSA 5.2 ng/ml (0,5-29); mean weight resection 20 gs. 22% biopsy previously by high PSA, mean PSA 14 ng/ml (4,8- 30). Gleason average 5 (mean 4.8), rank 3-8. pT1a 66%, pT1b 33%. Treatment: 57% follow-up watched without treatment (wait and see); 18% hormonal treatment; 3% finasteride; 9% Radical Prostatectomy; 9% radiotherapy. Follow Lost 4%. Mean follow-up 47.19 months (12-96). Tumor progression 13.3% (10 patients). Specific CPI mortality 2.6% (2 patients). We didn´t observe significant differences between the prevalence of CPI in both groups (APS and RTU-P). The detected tumours were mainly well differentiated and in stage pT1a. In more than half of the cases an expectant attitude without treatment was decided. 13,3% of tumor progression after 47.19 months of follow mean and specific CPI mortality 2.6%." @default.
• W2102481471 created "2016-06-24" @default.
• W2102481471 creator A5011734940 @default.
• W2102481471 creator A5014938378 @default.
• W2102481471 creator A5032651881 @default.
• W2102481471 creator A5065385199 @default.
• W2102481471 creator A5068163191 @default.
• W2102481471 creator A5072232315 @default.
• W2102481471 date "2006-01-01" @default.
• W2102481471 modified "2023-10-13" @default.
• W2102481471 title "Estudio clínico-patológico sobre el cáncer de próstata incidental en pacientes intervenidos bajo el supuesto diagnóstico de HBP sintomática" @default.
• W2102481471 cites W1976695896 @default.
• W2102481471 cites W1992651972 @default.
• W2102481471 cites W2021694611 @default.
• W2102481471 cites W2072070163 @default.
• W2102481471 cites W2075795442 @default.
• W2102481471 cites W2128641418 @default.
• W2102481471 cites W2134105728 @default.
• W2102481471 cites W2180437314 @default.
• W2102481471 cites W2414542109 @default.
• W2102481471 cites W2414618333 @default.
• W2102481471 cites W2464972870 @default.
• W2102481471 doi "https://doi.org/10.1016/s0210-4806(06)73393-9" @default.
• W2102481471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16703727" @default.
• W2102481471 hasPublicationYear "2006" @default.
• W2102481471 type Work @default.
• W2102481471 sameAs 2102481471 @default.
• W2102481471 citedByCount "4" @default.
• W2102481471 countsByYear W21024814712014 @default.
• W2102481471 countsByYear W21024814712018 @default.
• W2102481471 crossrefType "journal-article" @default.
• W2102481471 hasAuthorship W2102481471A5011734940 @default.
• W2102481471 hasAuthorship W2102481471A5014938378 @default.
• W2102481471 hasAuthorship W2102481471A5032651881 @default.
• W2102481471 hasAuthorship W2102481471A5065385199 @default.
• W2102481471 hasAuthorship W2102481471A5068163191 @default.
• W2102481471 hasAuthorship W2102481471A5072232315 @default.
• W2102481471 hasBestOaLocation W21024814712 @default.
• W2102481471 hasConcept C120665830 @default.
• W2102481471 hasConcept C121332964 @default.
• W2102481471 hasConcept C29456083 @default.
• W2102481471 hasConcept C61511704 @default.
• W2102481471 hasConcept C71924100 @default.
• W2102481471 hasConceptScore W2102481471C120665830 @default.
• W2102481471 hasConceptScore W2102481471C121332964 @default.
• W2102481471 hasConceptScore W2102481471C29456083 @default.
• W2102481471 hasConceptScore W2102481471C61511704 @default.
• W2102481471 hasConceptScore W2102481471C71924100 @default.
• W2102481471 hasIssue "1" @default.
• W2102481471 hasLocation W21024814711 @default.
• W2102481471 hasLocation W21024814712 @default.
• W2102481471 hasLocation W21024814713 @default.
• W2102481471 hasOpenAccess W2102481471 @default.
• W2102481471 hasPrimaryLocation W21024814711 @default.
• W2102481471 hasRelatedWork W1580426574 @default.
• W2102481471 hasRelatedWork W1970383787 @default.
• W2102481471 hasRelatedWork W1999344589 @default.
• W2102481471 hasRelatedWork W2043123170 @default.
• W2102481471 hasRelatedWork W2089620537 @default.
• W2102481471 hasRelatedWork W2275480158 @default.
• W2102481471 hasRelatedWork W3095306390 @default.
• W2102481471 hasRelatedWork W3209251735 @default.
• W2102481471 hasRelatedWork W4238089809 @default.
• W2102481471 hasRelatedWork W4241346791 @default.
• W2102481471 hasVolume "30" @default.
• W2102481471 isParatext "false" @default.
• W2102481471 isRetracted "false" @default.
• W2102481471 magId "2102481471" @default.
• W2102481471 workType "article" @default.